1. Generics Bulletin
  2. >>Business
  3. >>Deals

Standalone Sandoz And Biocon’s Biosimilars: 2022’s Biggest Deals

Apotex Moves From Family To Private Equity, Among Other Transactions

 
• By Dean Rudge

The acquisition and consolidation mania that gripped industry in the middle half of the last decade may seem like a distant dream but players continued to spend cash where it could be justified in 2022, while raising much-needed capital to fund their endeavors.

M&A
Several of industry's major players made moves in 2022 • Source: Cagkan Sayin/Alamy Stock Photo (Cagkan Sayin / Alamy Stock Photo/Alamy Stock Photo)

A long-rumored spin-off proposing the creation of the “number one standalone European generics company and a global leader in generics and biosimilars,” an acquisition valued at more than $3bn in the burgeoning biosimilars sector, and a landmark special purpose acquisition company (SPAC) merger delivering a much-desired public listing – 2022 proved another busy year for dealmaking.

In a year dogged by geopolitical turmoil, plunging stock and rising energy prices, as well as supply chain issues, industry marched on, adding to their portfolios where they perceived value could be created or else

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business

Dr Reddy’s Gears For Tariffs Scenario To Ensure No US Supply Disruption

 
• By Anju Ghangurde

Dr. Reddy's Laboratories preps for potential US tariffs, focusing on sustaining product supply and collaborating with customers on inventories. A recent US plant sale, the firm stressed, was unrelated to tariffs and underlines its openness to ‘make in the US’, where it launched 18 products in fiscal 2025.

Cutting Out The Middlemen? Trump’s Pricing Order Offers Opportunity On PBMs

 
• By Dave Wallace

Donald Trump’s executive order on most-favored-nation prescription drug pricing could provide positive opportunities for the off-patent industry, although US generics and biosimilars association the AAM suggested that the administration might do more good by focusing elsewhere.

Pfizer Discusses Tariffs Amid International Slump For Oncology Biosimilars Revenue

 
• By Adam Zamecnik

Reflecting conversations across the wider pharmaceutical industry, Pfizer’s earnings call for the first quarter of 2025 focused on the sector’s response to the potential imposition of tariffs by the Trump administration.